Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers
Clinical and Translational Medicine · 2026-01 · 16 (1)
DOI: 10.1002/ctm2.70591 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 10.01.2026. Verfasst von Maria Rosaria Lamia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Bevacizumab, Ovarian Neoplasms, Biomarkers, Tumor, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana Ricerca sul Cancro (AIRC), 25932, Ministry of Health.
Abstract (Originalsprache)
Angiogenesis, driven by the vascular endothelial growth factor (VEGF)/VEGFR signalling axis under hypoxic conditions, is one of the hallmarks of ovarian cancer (OC), contributing to tumour progression, metastatic dissemination and immune evasion. Hypoxia‐induced angiogenic signalling sustains tumour growth and shapes an immunosuppressive tumour microenvironment, while homologous recombination deficiency (HRD) has been associated with increased tumour hypoxia and pro‐angiogenic signalling. Conversely, VEGF pathway inhibition may exacerbate DNA damage and modulate immune cell trafficking, providing a strong biological rationale for synergy between anti‐angiogenic agents, PARP inhibitors (PARPi), and immune checkpoint inhibitors. Bevacizumab, a humanised monoclonal antibody targeting VEGF‐A, represents a pivotal therapeutic agent in OC management by inhibiting tumour angiogenesis and inducing transient vascular normalisation. Its clinical efficacy has been demonstrated as maintenance therapy in the first‐line setting, alone or in combination with PARPi for HRD‐positive disease, and in the recurrent setting both in platinum‐sensitive and platinum‐resistant disease. Despite these benefits, variability in patient response highlights the unmet need for validated predictive biomarkers. Circulating, tissue‐based and molecular biomarkers have been investigated, including angiogenic factors (Tie2/Ang1 axis, interleukin‐6 [IL‐6] and chitinase‐3‐like protein [YKL‐40]), VEGF‐A isoforms, microvessel density, EGFR/ADAM17 signalling, angiomiRs and transcriptional subtypes with mesenchymal and proliferative phenotypes showing greater sensitivity to anti‐angiogenic strategies. Although HRD status holds prognostic relevance and selected microRNAs show emerging potential, no biomarker has yet been validated to predict benefit from bevacizumab in clinical practice. Translational analyses from the MITO16A/MaNGO OV‐2 program, highlight challenges such as assay standardisation, multiplicity correction and external validation, while identifying tumour immune infiltration patterns, TP53 mutation classes and composite HRD assessments as areas of further investigation. In conclusion, bevacizumab remains an integral component of OC treatment. Future progress will depend on biomarker‐driven, prospectively designed clinical trials and the integration of multi‐omic data and machine learning approaches to enable precision application of anti‐angiogenic strategies, maximising clinical benefit while minimising toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Naples, Italy.
- Department of Precision Medicine, Università Degli Studi della Campania, Napoli, Italy.
- Molecular Oncology Unit, Centro di Riferimento Oncologico di Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
- Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, Verona, Italy.
Förderung
- Associazione Italiana Ricerca sul Cancro (AIRC)
- 25932
- Ministry of Health
- Ministry of Health Ricerca Corrente
- Ministero della Salute CRO Aviano Ricerca Corrente
- Ministeriet Sundhed Forebyggelse
Zitieren
APA
Lamia, M. R., Perri, E., Baldassarre, G., Pignata, S., D'Alessio, C., Limongello, D., & Basso-Valentina, F. (2026). Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers. Clinical and Translational Medicine, 16(1). https://doi.org/10.1002/ctm2.70591
Vancouver
Lamia MR, Perri E, Baldassarre G, Pignata S, D'Alessio C, Limongello D, et al. Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers. Clinical and Translational Medicine. 2026;16(1). doi:10.1002/ctm2.70591
BibTeX
@article{Lamia2026,
author = {Lamia, Maria Rosaria and Perri, Erica and Baldassarre, Gustavo and Pignata, Sandro and D'Alessio, Chiara and Limongello, Davide and Basso-Valentina, Francesca},
title = {Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {1},
doi = {10.1002/ctm2.70591}
}
EUVIMED